- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02549404
Phase 3 Study of KHK7580
July 2, 2017 updated by: Kyowa Kirin Co., Ltd.
Phase 3 Study of KHK7580 (A Long-term Study of KHK7580 in Subjects With Secondary Hyperparathyroidism Receiving Hemodialysis)
This long-term study is designed to evaluate safety and efficacy of KHK7580 orally administered once daily for 52 weeks for patients with secondary hyperparathyroidism receiving hemodialysis.
Study Overview
Study Type
Interventional
Enrollment (Actual)
137
Phase
- Phase 3
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Tokyo, Japan
- For additional information regarding investigative sites for this trial, contact Kyowa Hakko Kirin
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
20 years and older (Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Personally submitted written voluntary informed consent to participate in the study
- Stable chronic renal disease treated with hemodialysis 3 times weekly for at least 12 weeks before screening
- Intact PTH level of > 240 pg/ml at screening (except subjects receiving cinacalcet hydrochloride at screening)
Exclusion Criteria:
- Change in dose or dosing regimen of cinacalcet hydrochloride or activated vitamin D drug or its derivative, phosphate binder, or calcium preparation within 2 weeks before screening; or start of treatment with such drugs within 2 weeks before screening;
- Parathyroidectomy and/or parathyroid intervention within 24 weeks before screening;
- Severe heart disease;
- Severe hepatic dysfunction;
- Uncontrolled hypertension and/or diabetes;
- Treatment with an investigational product (drug or medical device) in a clinical study or any study equivalent to clinical study within 12 weeks before screening;
- Primary hyperparathyroidism;
- Other conditions unfit for participation in this study at the discretion of the investigator or subinvestigator.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: KHK7580
|
Oral administration
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with adverse events
Time Frame: Up to 52 weeks
|
Adverse Event collection and assessment
|
Up to 52 weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Percentage of subjects achieving intact parathyroid hormone (PTH) level of ≥ 60 pg/mL and ≤ 240 pg/mL
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
Percentage of subjects achieving a mean percent decrease in intact PTH level of ≥ 30% (percent change ≤ -30%) from baseline
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
Mean percent change in intact PTH level from baseline
Time Frame: Up to 52 weeks
|
Up to 52 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
September 28, 2015
Primary Completion (Actual)
December 6, 2016
Study Completion (Actual)
December 28, 2016
Study Registration Dates
First Submitted
September 9, 2015
First Submitted That Met QC Criteria
September 11, 2015
First Posted (Estimate)
September 15, 2015
Study Record Updates
Last Update Posted (Actual)
July 5, 2017
Last Update Submitted That Met QC Criteria
July 2, 2017
Last Verified
July 1, 2017
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 7580-011
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Secondary Hyperparathyroidism
-
The Second Hospital of Nanjing Medical UniversityRecruitingSecondary Hyperparathyroidism;ParathyroidectomyChina
-
Phramongkutklao College of Medicine and HospitalCompletedAlfacalcidol, Secondary Hyperparathyroidism, Hemodialysis
-
Chang Gung Memorial HospitalCompletedSecondary Hyperparathyroidism Due to Renal CausesTaiwan
-
Fundación SenefroAbbVie; Effice Servicios Para la Investigacion S.L.CompletedSecondary Hyperparathyroidism Due to Renal CausesSpain
-
Min-Sheng General HospitalTaipei Medical University; Taipei Medical University Shuang Ho Hospital; National... and other collaboratorsCompletedHyperparathyroidism; Secondary, RenalTaiwan
-
Shanghai Zhongshan HospitalUnknownHyperparathyroidism; Secondary, Renal
-
Shanghai Hengrui Pharmaceutical Co., Ltd.Active, not recruiting
-
Sanwa Kagaku Kenkyusho Co., Ltd.Completed
-
Sanwa Kagaku Kenkyusho Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Deltanoid PharmaceuticalsCompletedSecondary HyperparathyroidismUnited States
Clinical Trials on KHK7580
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.Completed
-
Kyowa Kirin Co., Ltd.CompletedHyperparathyroidismJapan
-
Kyowa Kirin Co., Ltd.CompletedSecondary HyperparathyroidismJapan
-
Kyowa Kirin Co., Ltd.CompletedPrimary Hyperparathyroidism | Parathyroid CarcinomaJapan
-
Kyowa Kirin Co., Ltd.Kyowa Hakko Kirin China Pharmaceutical Co., LTD.; Kyowa Kirin Korea Co., Ltd.CompletedSecondary HyperparathyroidismChina, Hong Kong, Korea, Republic of, Taiwan